source
- Gilead says its oncology and inflammation portfolio has reached critical mass after series of acquisitionsGilead Sciences CEO Daniel O’Day told Fierce that the company’s push into oncology and inflammation has now reached a point of critical mass, with a pipeline that spans early research to late‑stage…
- Research on orexin and narcolepsy earns Lasker Award for Yanagisawa and MignotMasashi Yanagisawa and Emmanuel Mignot were honored with the Lasker Award for their work uncovering the role of orexin in narcolepsy. The award was announced on September 9, 2026. Their research b…